[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

661-949-4175

Email address

diane.bowers@bsci.com

Condition

Parkinson Disease

Treatment type

Interventional

Investigational product

Vercise Deep Brain Stimulation System

Phase

N/A

Sponsor

Boston Scientific Corporation

ClinicalTrials.gov identifier

NCT03037398

Study number

A4063

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The objective of this study is to evaluate the performance of novel DBS programming methods compared to traditional programming methods.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Implanted bilaterally in STN with a Verciseā„¢ DBS system for Parkinson's disease for at least six months and programming optimized according to standard of care with no changes to electrode configuration of primary settings for at least four weeks.
  2. Able to understand the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed.
  3. Be at least 18 years of age.
Exclusion criteria
  1. Any significant psychiatric problems, including unrelated clinically significant depression as determined by the investigator.
  2. Device must be implanted on label.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site